Summary
The effects of a beta-blocker, carvedilol, on peripheral hemodynamics and hemorheologic parameters were evaluated in 11 geriatric patients with essential hypertension [3 men and 8 women aged 62–79 years (mean, 68.6 years)]. Carvedilol was given orally after breakfast at a dose of 10 or 20 mg daily for 8 weeks. Peripheral hemodynamics, the common carotid arterial flow, and hemorheologic parameters were determined twice prior to administration and after 4 and 8 weeks of carvedilol treatment. The common carotid arterial flow was determined using the pulsed Doppler method. Peripheral hemodynamics were assessed by venous occlusion plethysmography. The hemorheologic parameters assessed include erythrocyte aggregation, erythrocyte deformability, plasma viscosity, whole-blood hematocrit, and platelet function tests. Erythrocyte aggregation was measured using an Erythrocyte Aggregometer MA-1 (Myrenne, USA), taking a high shear rate of 600 s\t-1 and a low shear rate of 3 s\t-1 as the indices. Statistical comparisons of values before and after carvedilol administration were made using the paired Student'st-test. Systolic and diastolic blood pressure were decreased by carvedilol. The common carotid arterial flow was increased, and peripheral hemodynamics were improved by carvedilol. Erythrocyte aggregation (measured at both a high and a low shear rate) and plasma viscosity were decreased, erythrocyte deformability was increased, and levels of circulating platelet aggregates were also improved by carvedilol. This improvement of hemorheologic variables may contribute to prevention of the initiation and progression of thrombosis and atherosclerosis in geriatric patients with essential hypertension.
Similar content being viewed by others
References
Moellendorff E van, Abshagen U, Akpan W, Neugebauer G, Schroeter E (19869 Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clin Pharmacol Ther 39: 677–682
Strein K, Sponer B, Mueller-Beckmann B, Bartsch W (1987) Pharmacological profile of a carvedilol, a compound with beta-blocking and vasodilating properties. J Cardiovasc Pharmacol 10 [Suppl 11]: S33-S41
Abshagen U (1987) A new molecule with vasodilating and beta-adrenoceptor blocking properties. J Cardiovasc Pharmacol 10 [Suppl 11]: S23-S32
Cubeddu LX, Fuenmayer N, Varin F, Villagra VG, Colindres RE, Powell JR (1987) Mechanism of the vasodil-ory effect of carvedilol in normal volunteers: a comparison with labetaolol. J Cardiovasc Pharmacol 10 [Suppl 11]: S81-S84
Hashimoto H, Tanaka M, Kanda A, Akashi A (1988) Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats. Drugs 26 [Suppl 6]: 31–36
Hattori Y, Nakaya H, Endou M, Nakao Y, Kanno M (1989) Vascular effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery. J Cardiovasc Pharmacol 13: 572–579
Sponer G, Bartsch W, Strein K, Mueller-Beckmann B, Peters P (1985) Hemodynamic profile of carvedilol and propranolol in conscious spontaneously hypertensive rats and normotensive dogs. International Cardiovascular Pharmacotherapy Symposium, May 22–25,1985, Geneva
Nagakawa Y, Onuki Y, Orimo H, Harasawa M (1986) Pulsed Doppler: diameter, blood flow velocity and volume flow of the common carotid artery in cerebral infarction. Jpn J Stroke 8: 600–602
Nagakawa Y, Orimo H, Harasawa M (1984) Effect of age, sex and other physical parameters on peripheral hemodynamics in normal subjects. J Cardiogr 14 [Suppl V]: 76–78
Reid HL, Barnes AJ, Lock PJ, Dormandy JA, Dormandy TL (1976) A simple method for measuring erythrocyte deformability. J Clin Pathol 29: 855–858
Schmid-Schoenbein H, Kline KA, Heinlich L, Volger E, Fischer T (1975) Microrheology and light transmission of blood: velocity of red cell aggregate formation. Pfluegers Arch 354: 299–317
Nagakawa Y (1980) Factors influencing the platelet aggregation test. Jpn J Geriatr 17: 7–17
Wu KK, Hoak JC (1974) A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet II: 924–926
Chien S (1977) Blood rheology in hypertension and cardiovascular diseases. Cardiovasc Med 2: 356–360
Dintenfass L (1977) Viscosity factors in hypertensive and cardiovascular diseases. Cardiovasc Med 2: 337–342
Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH (1981) Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects: role of fibrinogen and concentration. Am J Med 70: 1195–1202
Jan KM, Chien S, Bigger IT Jr (1975) Observations on blood viscosity changes after acute myocardial infarction. Circulation 51: 1079–1084
Forconi S, Guerrini M, Pieragalli D, Acciavatti A, DelBigo C, Galigani C, Diperri T (1983) Hemorheological changes in ischemic heart disease. Ric Clin Lab 13 [Suppl 3]: 195–208
Chien S (1975) Biophysical behavior of red cells in suspsensions. In: Surgenor DM (ed) The red blood cell, vol 2, 2nd edn. Academic Press, New York, pp 1031–1133
Gaetano G de, Bertele V, Cerletti C (1987) Pharmacology of antiplatelet drugs. In: MacIntyre DE, Gordon JL (eds) Platelets in biology and pathology III. Elsevier Science, Amsterdam New York Oxford
Scott CK, Persico FJ, Carpentier K, Chasin M (1980) The effect of flunarizine, a new calcium antagonist, on human red blood cells in vitro. Angiology 31: 320–330
Van Neuten JM, Vanhoutte PM (1980) Improvement of tissue perfusion with inhibitors of calcium ion influx. Biochem Pharmacol 29: 479–481
Plishker GA, Gitelman HJ (1977) Calcium dependent ATP losses in intact red blood cells without cellular accumulations of calcium. J Membrane Biol 35: 309–318
Larsen FL, Katz S, Roufogalis BD, Brooks DE (1981) Physiological shear stresses enhance the Ca2+ permeability of human erythrocytes. Nature 294: 667–668
Quist EE (1980) Regulation of erythrocyte membrane shape by calcium. Biochem Biophys Res Commun 92: 631–637
Vanhoutte P, Amery A, Birkenhaeger W, Breckenridge A, Buehler F, Distler A, Dormandy J, Doyle A, Fronlich E, Hansson L, Hedner T, Hollenberg N, Jensen HE, Lund-Johansen P, Meyer P, Opie L, Robertson I, Safar M, Schalekamp M, Symoens J, Trap-Jensen J, Zanchetti A (1988) Serotonergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 11: 111–133
De Cree J, Leempoels J, Demoen B, Verhaegen H (1985) Ketanserin and red blood cell sodium content in hypertension. J Cardiovasc Pharmacol [Suppl] 7: S41-S43
Fuchs J, Weinberger I, Rotenberg Z, Erdberg A, Davidson E, Joshua H, Agmon J (1984) Plasma viscocity in ischemic heart disease. Am Heart J 108: 435–439
Sundberg S, Tiihonen K, Gondin A (1987) Vasodilatory effects of carvedilol and pindolol. J Cardiovasc Pharmacol 10 [Suppl 11]: 76–80
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nagakawa, Y., Akedo, Y., Kaku, S. et al. Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension. Eur J Clin Pharmacol 38 (Suppl 2), S115–S119 (1990). https://doi.org/10.1007/BF01409478
Issue Date:
DOI: https://doi.org/10.1007/BF01409478